drug · antibody
nemolizumab
Phase 2updated 3mo agoby Galderma SA🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 2 investigational indications.
targets
Interleukin-31 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying nemolizumab
- phase2Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
- phase2A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
- phase2A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- phase2An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
- phase4Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
- phase3A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- phase2Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
- phase3To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
News(3)
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 3d ago
- Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOAttovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for b…fiercebiotech · 9d ago
- Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.fiercebiotech · 15d ago
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that